Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Janssen Research & Development, LLC
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants have histologically or cytologically confirmed B-cell non-Hodgkin's Lymphoma (NHL) according to the 2022 World Health Organization (WHO) classification with relapsed or refractory disease
Participants have measurable disease or meet all requirements for adequate response assessment as defined by the appropriate disease response criteria at screening
Participants have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Participants have a life expectancy of greater than or equal to (\>=) 12 weeks
Be willing and able to adhere to the lifestyle restrictions specified in the protocol
You may not be if
Participant with active or prior history of B-cell NHL involving the central nervous system (CNS) and leptomeningeal involvement
History of malignancy (other than the disease under study in the cohort to which the participant is assigned) within 1 year prior to the first administration of study treatment.
For Part A and B: Participant having known allergies, hypersensitivity, or intolerance to the excipients of JNJ-88998377
Participant had major surgery or had significant traumatic injury within 30 days before first dose of study treatment or has not recovered from surgery and must not have major surgery planned during the time the participant is receiving study treatment
Participant received an autologous stem cell transplant less than or equal to (\<=) 3 months before the first dose of study treatment
